Skip to main content

Inotiv, Inc. (NOTV) Stock Forecast

Data as of May 2, 2026

Healthcare · Current price $0.31 (+7.58%)

Consensus Target
$3.00
Upside
+861.2%
Analysts
2
Rating
Buy(2.00)

Price Target Range

Low $3.00High $3.00

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Buy
Strong Buy0
Buy1
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

DateAnalystFirmPrice TargetUpside
Dec 4, 2025Frank TakkinenLake Street$3.00+861.2%
Dec 4, 2024Frank TakkinenLoop Capital Markets$6.00+1822.5%
Sep 30, 2024Frank TakkinenLoop Capital Markets$4.00+1181.6%
Jan 24, 2023David WindleyJefferies$8.00+2463.3%

NOTV vs Sector & Market

MetricNOTVHealthcare AvgLarge Cap Avg
Analyst Rating2.002.242.41
Analyst Count2818
Target Upside+861.2%+1149.2%+14.9%
P/E Ratio-0.146.8731.19

Revenue Estimates

PeriodLowAvgHigh#
2026-09-30$529M$530M$530M1
2027-09-30$556M$558M$561M2
2028-09-30$586M$587M$587M1

EPS Estimates

PeriodLowAvgHigh#
2026-09-30$-2.27$-2.27$-2.261
2027-09-30$-1.84$-1.81$-1.782
2028-09-30$0.00$0.00$0.001

Frequently Asked Questions

What is the analyst consensus for NOTV?

The consensus among 2 analysts covering Inotiv, Inc. (NOTV) is Buy with an average price target of $3.00.

What is the highest price target for NOTV?

The highest price target for NOTV is $8.00, set by David Windley at Jefferies on 2023-01-24.

What is the lowest price target for NOTV?

The lowest price target for NOTV is $3.00, set by Frank Takkinen at Lake Street on 2025-12-04.

How many analysts cover NOTV?

2 analysts have issued ratings for Inotiv, Inc. in the past 12 months.

Is NOTV a buy or sell right now?

Based on 2 analyst ratings, NOTV has a consensus rating of Buy (2.00/5) with a +861.2% upside to the consensus target of $3.00.

What are the earnings estimates for NOTV?

Analysts estimate NOTV will report EPS of $-2.27 for the period ending 2026-09-30, with revenue estimated at $530M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.